分析利妥昔单抗联合CHOP方案对B细胞型非霍奇金淋巴瘤患者临床疗效及远期生存率的影响  

Analysis of the Clinical Efficacy and Long-term Survival of the Combination of Rituximab and CHOP Regimen in Patients with B-cell Non Hodgkin's Lymphoma

作　　者：胡坤鹏 王晓霞 李文[3] HU Kunpeng;WANG Xiaoxia;LI Wen(Tengzhou Traditional Chinese Medicine Hospital,Tengzhou 277500,Shandong,China;Tai'an 88 Hospital,Tai'an 271000,Shandong,China;Tengzhou Central People's Hospital,Tengzhou 277500,Shandong,China)

机构地区：[1]滕州市中医医院,山东滕州277500 [2]泰安八十八医院,山东泰安271000 [3]滕州市中心人民医院,山东滕州277500

出　　处：《系统医学》2025年第3期26-29,共4页Systems Medicine

摘　　要：目的探讨利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤(B cell non-Hodgkin's lymphoma,B-NHL)的疗效及对远期生存率的影响。方法非随机选取2018年1月—2019年12月滕州市中医医院收治的60例B-NHL患者为研究对象,根据治疗方案差异分为两组,每组30例。A组接受CHOP治疗,B组接受利妥昔单抗联合CHOP治疗,对比两组的疗效及安全性。结果与A组相比,B组的乳酸脱氢酶、胸苷激酶-1及血管内皮生长因子水平更低,生存率更高,差异有统计学意义(P均<0.05)。B组的治疗总有效率为86.67%(26/30),高于A组的63.33%(19/30),差异有统计学意义(χ^(2)=4.356,P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P均>0.05)。结论利妥昔单抗联合CHOP治疗B-NHL能提高临床疗效及患者远期生存率,且安全性良好。Objective To investigate the efficacy of rituximab combined with CHOP regimen in the treatment of Bcell non-Hodgkin's lymphoma(B-NHL)and its influence on long-term survival rate.Methods A total of sixty patients with B-NHL admitted to Tengzhou Traditional Chinese Medicine Hospital from January 2018 to December 2019 were non-randomly selected as the study objects and divided into two groups with thirty cases in each group according to the difference in treatment regimen.Group A was treated with CHOP and group B was treated with rituximab combined with CHOP.The efficacy and safety of the two groups were compared.Results Compared with group A,the levels of lactate dehydrogenase,thymidine kinase-1 and vascular endothelial growth factor in group B were lower,and the survival rate was higher,the differences were statistically significant(all P<0.05).The total effective rate of group B was 86.67%(26/30),which was higher than 63.33%(19/30)of group A,and the difference was statistically significant(χ^(2)=4.356,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(all P>0.05).Conclusion Rituximab combined with CHOP in the treatment of B-NHL can improve the clinical efficacy and long-term survival rate of patients,and the safety is good.

关 键 词：利妥昔单抗 CHOP方案 B细胞型非霍奇金淋巴瘤 临床疗效 远期生存率 

分 类 号：R551.2[医药卫生—血液循环系统疾病]